Skip to search formSkip to main contentSkip to account menu

AEE 788

Known as: AEE-788, AEE788 
An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

NVP-AEE788

Broader (1)

Purines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models
Some lines of evidence suggest that tumors, including ependymoma, might arise from a subpopulation of cells, termed cancer stem… 
2009
2009
A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation.
OBJECT The study of tumor cell growth and invasion in cancer biology is often limited by the inability to visualize tumor cell… 
2006
2006
Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on…
Inhibiting epidermal growth factor receptor (EGF‐R) and vascular endothelial growth factor receptor (VEGF‐R) activation with… 
2006
2006
Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer
Purpose: Patients with radioiodine-resistant follicular thyroid cancer (FTC) have a poor prognosis, if metastasized, with… 
2006
2006
Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis.
Oral treatment with the dual-receptor tyrosine kinase inhibitor AEE788 effectively reduces the number of peritumoral lymphatic… 
Highly Cited
2005
Highly Cited
2005
Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors
Purpose: We determined whether the administration of the tyrosine kinase inhibitor, AEE788, which targets the epidermal growth… 
Highly Cited
2005
Highly Cited
2005
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Patients suffering from bone metastases of follicular thyroid carcinoma (FTC) have a poor prognosis because of the lack of… 
2005
2005
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose…
3028 Background: AEE788 is an orally active, small-molecule, multitargeted kinase inhibitor with potent inhibitory activity… 
2005
2005
AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results
3039 Background: AEE788 is an oral inhibitor with potent activity against multiple tyrosine kinases including EGFR, HER2, and… 
Highly Cited
2004
Highly Cited
2004
Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)